April 12 (Reuters) - Bayer AG statement on decision in glyphosate litigation in California::* Will comply with court's mediation order in good faith.* Will remain focused on defending safety of glyphosate-based herbicides in court, including in Pilliod case, and through appeal in Johnson and post-trial proceedings in Hardeman.* Reliable science supports safety of Roundup.
Full Article
April 4 (Reuters) - Novozymes ::CO AND BIOAG ANNOUNCE CONTINUATION WITH BAYER AS CORE PARTNER.CO IS PURSUING A MULTI-PARTNER SETUP, WITH TWO NEW PARTNERS, UNIVAR SOLUTIONS AND UPL.THE 2019 ORGANIC SALES GROWTH OUTLOOK FOR NOVOZYMES AND FOR THE AG & FEED BUSINESS IS MAINTAINED.THE LONG-TERM BIOAG TARGET OF SUPPLYING TECHNOLOGY TO 250-500 MILLION ACRES IS ALSO MAINTAINED.EBIT MARGIN,NET PROFIT GROWTH,FREE CASH FLOW BEFORE ACQUISITIONS AND ROIC GUIDANCE FOR 2019 UPDATED DUE TO ONE-OFF DEFERRED INCOME RELEASE.THE EBIT MARGIN GUIDANCE FOR 2019 IS INCREASED FROM 28-29% TO 29-30%.THE ROIC GUIDANCE FOR 2019 IS INCREASED FROM ABOUT 23% TO ABOUT 24%.NET PROFIT GROWTH GUIDANCE FOR 2019 INCREASED FROM 0-5% TO 5-10%.
Full Article
March 27 (Reuters) - Bayer AG ::BAYER STATEMENT IN REACTION TO PHASE TWO VERDICT IN FAVOR OF PLAINTIFF IN CASE OF HARDEMAN V MONSANTO.BAYER WILL APPEAL THIS VERDICT."DISAPPOINTED WITH JURY'S DECISION".VERDICT IN THIS TRIAL HAS NO IMPACT ON FUTURE CASES AND TRIALS, AS EACH ONE HAS ITS OWN FACTUAL AND LEGAL CIRCUMSTANCES .
Full Article
March 14 (Reuters) - Bayer AG ::BAYER NEWS RELEASE: PHASE III CLINICAL TRIAL WITH BAYER’S NIFURTIMOX DEMONSTRATES SAFETY AND EFFICACY OF NEW FORMULATION TO TREAT CHILDREN WITH CHAGAS DISEASE.STUDY MET ITS PRIMARY ENDPOINT BY DEMONSTRATING SUPERIORITY OF 60-DAY NIFURTIMOX TREATMENT COMPARED WITH HISTORICAL PLACEBO CONTROL IN SEROLOGICAL RESPONSE AT ONE YEAR AFTER END OF TREATMENT.IN OVERALL STUDY POPULATION, SEROLOGICAL RESPONSE TO A SHORTER NIFURTIMOX TREATMENT DURATION OF 30 DAYS WAS LOWER WHEN COMPARED TO 60-DAY TREATMENT.
Full Article
March 5 (Reuters) - Bayer AG ::BAYER SUBMITS DAROLUTAMIDE FOR MARKETING AUTHORIZATION IN JAPAN.REGULATORY SUBMISSION BASED ON POSITIVE DATA FROM PHASE III ARAMIS STUDY.SUBMITTED AN APPLICATION FOR MARKETING AUTHORIZATION IN JAPAN FOR DAROLUTAMIDE FOR THE TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC).
Full Article
Feb 28 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC RECEIVES MILESTONE PAYMENT FOR START OF SECOND PHASE II TRIAL IN ITS MULTI-TARGET ALLIANCE WITH BAYER.SMALL MOLECULE FROM ITS MULTI-TARGET ALLIANCE WITH BAYER HAS ADVANCED INTO PHASE II CLINICAL DEVELOPMENT FOR TREATMENT OF PERSISTENT CHRONIC COUGH.AS A RESULT OF TRIAL INITIATION, EVOTEC RECEIVED A PAYMENT OF EUR 3 M.
Full Article
Feb 27 (Reuters) - Orion Oyj ::ANNOUNCES COMPLETION OF ROLLING SUBMISSION OF NEW DRUG APPLICATION (NDA) FOR DAROLUTAMIDE TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA).CO'S PARTNER BAYER HAS BEEN GRANTED FAST TRACK DESIGNATION BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR DAROLUTAMIDE IN MEN WITH NMCRPC.
Full Article
Feb 14 (Reuters) - Orion Oyj ::ORION'S AND BAYER'S DAROLUTAMIDE SHOWS SUBSTANTIAL EFFICACY AND A FAVOURABLE SAFETY PROFILE IN THE TREATMENT OF PROSTATE CANCER IN THE ARAMIS TRIAL.POSITIVE TREND IN OVERALL SURVIVAL WITH A 29% REDUCTION IN RISK OF DEATH AT INTERIM ANALYSIS OF DAROLUTAMIDE IN ARAMIS TRIAL.POSITIVE TREND IN OVERALL SURVIVAL WAS AOBSERVED, ALL OTHER SECONDARY ENDPOINTS DEMONSTRATED BENEFIT IN FAVOR OF DAROLUTAMIDE.
Full Article
Jan 31 (Reuters) - Bayer AG ::BAYER AND KYOTO UNIVERSITY FORM RESEARCH ALLIANCE TO DISCOVER NEW TREATMENT APPROACHES AGAINST LUNG DISEASES (REMOVES REDUNDANT WORDS).GOAL OF RESEARCH ALLIANCE IS TO IDENTIFY SPECIFIC TARGETS AND PATHWAYS THAT ARE CAUSING DISEASE AND TO DISCOVER NEW TREATMENTS TO MODULATE THESE PATHWAYS AND PREVENT FURTHER LUNG FUNCTION DECLINE.
Full Article
Jan 22 (Reuters) - PetIQ Inc ::PETIQ, INC. ANNOUNCES AMICABLE LEGAL RESOLUTION.PETIQ INC - BAYER HEALTHCARE & CO'S SUPPLIER OF ADVECTA3 AND PETLOCK MAX HAVE RESOLVED BAYER'S PATENT INFRINGEMENT COMPLAINT REGARDING PRODUCTS.PETIQ INC - PETIQ TO CONTINUE OFFERING CUSTOMERS ITS ADVECTA3 AND PETLOCK MAX FORMULATIONS.
Full Article
Earnings vs. 
Estimates